CD8A and neoplasm: Considering the off-target effects of BRAF/MEKi therapy, such as a paradoxical activation of CD8+ T-cells, it seems conceivable that a longer initial treatment with TT might prime anti-tumor immunity towards a more durable response even after treatment cessation [36].